Longeveron LGVN 深 沪
等待开盘 12-03 09:30:00 美东时间
0.644
+0.014
+2.22%
华盛通- 最 高0.6876
- 今 开0.66
- 成交量 95.26万股
- 最 低 0.6101
- 昨 收 0.63
- 总市值 1373.84万
- 52周最高 2.24
- 市盈率 静 --
- 换手率 4.47%
- 52周最低 0.5906
- 委 比 27.27%
- 总股本 2133.29万
- 历史最高 450.00
- 量 比 2.00
- 振 幅 12.30%
- 历史最低 0.5906
- 每 手 1
- 风险率 0.40%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Longeveron Reports Phase 2 Data Showing Stem Cell Therapy Laromestrocel Reduces Neuroinflammation And Preserves Brain Structure In Mild Alzheimer's Disease, To Presented At The 18th Clinical Trials On Alzheimer's Disease Conference, Held December 1-4, 2025
Results obtained in the Phase 2 placebo-controlled CLEAR-MIND clinical trial showed that treatment with stem cell therapy laromestrocel was associated with a reduction in MRI measured neuroinflammation compared to
12-02 01:02
Longeveron To Present Alzheimer's Disease Data At Clinical Trials On AD Conference In California
Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that its submission entitled
11-19 22:17
Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy
Longeveron Inc.获得美国专利第12,465,620号，涉及使用间充质干细胞治疗伴有炎症的年龄相关虚弱症。该专利有效期至2038年，可延长。年龄相关虚弱症表现为虚弱、低体力、运动迟缓、疲劳及体重减轻，与炎症相关。Longeveron的干细胞疗法Laromestrocel已完成临床试验，显示积极效果。
11-12 14:05
Longeveron Inc. Earnings Call: Mixed Sentiments Amid Clinical Progress
Longeveron Inc. (($LGVN)) has held its Q3 earnings call. Read on for the main h...
11-06 09:21
Earnings Scheduled For November 4, 2025
Companies Reporting Before The Bell • Sequans Communications (NYSE:SQNS) is lik...
11-04 19:12
Earnings Preview For Longeveron
Longeveron (NASDAQ:LGVN) is preparing to release its quarterly earnings on Tues...
11-04 05:03
Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR’s BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect
Longeveron announced the full enrollment of its pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential treatment for hypoplastic left heart syndrome (HLHS), a rare and severe congenital heart defect. ELPIS II is expected to release top-line results in the third quarter of 2026, following encouraging outcomes from the Phase 1 trial, which showed 100% transplant-free survival in treated patients up to age five. The thera...
10-27 13:15
Longeveron® to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
Longeveron Inc. is set to participate in the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, in New York, where it will hold one-on-one meetings with investors. The company, which focuses on developing cellular therapies for life-threatening, rare pediatric, and chronic aging-related conditions, is advancing Laromestrocel (Lomecel-B™), an allogeneic mesenchymal stem cell therapy with broad therapeutic potential. Longeveron...
10-06 13:15
Longeveron Appoints Dr. George Paletta to Board
Longeveron ( ($LGVN) ) just unveiled an announcement. On October 1, 2025, Longe...
10-02 04:47
George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors
Longeveron Inc. announced the election of George Paletta, Jr., MD, MBA, to its Board of Directors. Dr. Paletta, a nationally recognized orthopedic surgeon and entrepreneur, brings extensive experience in healthcare and business to the company. His expertise is expected to support Longeveron's stem cell therapy advancements targeting life-threatening conditions in children and the elderly. Longeveron is currently advancing multiple pipeline indica...
10-01 20:05
